MedPacto, Inc. (KOSDAQ:235980)
South Korea · Delayed Price · Currency is KRW 2,880.00
-80.00 (-2.70%)
Aug 12, 2026, 1:44 PM KST
MedPacto Revenue
MedPacto had revenue of 1.32B KRW in the quarter ending March 31, 2026, with 206.20% growth. This brings the company's revenue in the last twelve months to 4.79B, up 1,012.94% year-over-year. In the year 2025, MedPacto had annual revenue of 3.90B.
Revenue (ttm)
4.79B
Revenue Growth
+1,012.94%
P/S Ratio
21.20
Revenue / Employee
n/a
Employees
n/a
Market Cap
101.45B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.90B | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Macrogen | 199.60B |
| ORIENT BIO | 59.09B |
| Amicogen | 43.44B |
| CG Invites | 29.22B |
| Prestige BioPharma | 16.21B |
| Anterogen.Co.,Ltd. | 8.06B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.74B |